The fight over marijuana's federal status is moving from a hearing room to a courtroom. Just as the Drug Enforcement Administration wrapped up its administrative hearing on moving cannabis to Schedule III, the drug-testing industry and a pharmaceutical company asked a federal court to block the reclassification altogether.
Their central claim is that loosening marijuana's federal status would increase marijuana abuse. The federal government has countered that the challengers have pocketbook interests in keeping cannabis tightly restricted, a characterization the challengers dispute.
Why these challengers
A drug-testing company and a pharmaceutical maker both have business reasons to watch cannabis policy closely. Workplace and roadside drug testing is a large industry built around marijuana prohibition, and pharmaceutical companies compete with cannabis as a treatment option for pain, anxiety, and sleep. Reform advocates argue that is exactly why their opposition should be viewed skeptically.
What rescheduling would actually do
Moving marijuana from Schedule I to Schedule III would not legalize it nationwide, but it would remove one of the industry's biggest financial burdens: Section 280E of the federal tax code. Under 280E, businesses that 'traffic' in Schedule I or II substances cannot deduct ordinary expenses like rent and payroll, leaving many state-legal operators with effective tax rates far above other retailers. Ending 280E would matter enormously to New York's licensed dispensaries, many of which are still finding their footing.
What happens next
With the DEA's hearing concluded, the presiding judge is expected to issue a recommendation to the DEA Administrator, who makes the final call on whether to finalize the new rule. The lawsuit adds a parallel legal track that could slow the process or force it into appeals. Either way, the timeline is likely measured in months, not weeks.
For New York operators, the takeaway is simple: the policy that could reshape their tax bills is now being fought on two fronts at once. Cannabis products are for adults 21+.